Lower-extremity Dynamometry as a Novel Outcome Measure in a Double-blind, Placebo-controlled, Feasibility Trial of Intravenous Immunoglobulin (IVIG) for HIV-associated Myelopathy

by Jessica Robinson-Papp, MD, MS; Mary Catherine George, MM, PhD; Alexandra Nmashie, MD; Donald Weisz, PhD; and David M. Simpson, MD
Drs. Robinson-Papp, George, Nmashie and Simpson are with the Department of Neurology and Dr. Weisz is with the Department of Neurosurgery—all from the Icahn School of Medicine at Mount Sinai in New York, New York.

Innov Clin Neurosci. 2017;15(1–2):28–32

Tags: Dynamometry, human immunodeficiency virus (HIV), intravenous immunoglobulin (IVIG), myelopathy

Category: Assessment Tools, Movement Disorders, Neurodegenerative Disease, Neurology, Original Research, Past Articles, Primary Care, Technology, Trial Methodology